(02-03-2016, 04:17 PM)Katie Wrote: Sooooo... I think you can tell where I'm going with this, but just in case.
Both are anti androgens And counter each others unwanted effects, could this be the perfect synergy?
Probably one for Lotus I suspect 
Lol, I do see where your going. a quick point though, I do see (call it) a " perfect storm " or combination of herbs to induce puberty. The exact sequence ???, but....it would 11 beta HSD, combined with GH (growth hormone), possibly STAT5 protein, and protein kinase?.......first step is inhibiting cortisol though, then up-regulating GH through the HPA (hypothalamus pituitary axis).
But.......licorice is a ticking time bomb.
Quote:Its main constituent, glycyrrhizic acid, mimics miner- alocorticoids in its action (sodium reabsorb- tion and potassium secretion). The extent of metabolic and acid–base derangement can occasionally be severe enough to cause serious complications.
If you look at the pharmakonetics of both (LR & spiro) it's very interesting though. Spiro and its unintended consequence displaces estrogen from SHBG, this......we want. 11beta HSB inhibits cortisol.....this we want too. LR would be used for adrenal fatigue, however....only for 2 weeks at a time. Unfortunately, this risk is too great imo. What LR does for NBE is it inhibits 5 ar, upregulates E2, lowers prolactin, inhibit cortisol.
![[Image: attachment.php?aid=11501]](http://www.breastnexus.com/attachment.php?aid=11501)
Licorice abuse: time to send a warning message
http://www.ncbi.nlm.nih.gov/pmc/articles...454322.pdf
like activity of licorice root constituents: glabridin and glabrene, in vascular tissues in vitro and in vivo.
Somjen D1, Knoll E, Vaya J, Stern N, Tamir S.
Author information
Abstract
Post-menopausal women have higher incidence of heart diseases compared to pre-menopausal women, suggesting a protective role for estrogen. The recently Women's Health Initiative (WHI) randomized controlled trial concluded that the overall heart risk exceeded benefits from use of combined estrogen and progestin as hormone replacement therapy for an average of five years among healthy postmenopausal US women. Therefore, there is an urgent need for new agents with tissue-selective activity with no deleterious effects. In the present study, we tested the effects on vascular tissues in vitro and in vivo of two natural compounds derived from licorice root: glabridin, the major isoflavan, and glabrene, an isoflavene, both demonstrated estrogen-like activities.
Similar to estradiol-17beta (E2), glabridin (gla) stimulated DNA synthesis in human endothelial cells (ECV-304; E304) and had a bi-phasic effect on proliferation of human vascular smooth muscle cells (VSMC). Raloxifene inhibited gla as well as E2 activities. In animal studies, both intact females or after ovariectomy, gla similar to E2 stimulated the specific activity of creatine kinase (CK) in aorta (Ao) and in left ventricle of the heart (Lv). Glabrene (glb), on the other hand, had only the stimulatory effect on DNA synthesis in vascular cells, with no inhibition by raloxifene, suggesting a different mechanism of action. To further elucidate the mechanism of action of glb, cells were pre-incubated with glb and then exposed to either E2 or to gla; the DNA stimulation at low doses was unchanged but there was abolishment of the inhibition of VSMC cell proliferation at high doses as well as inhibition of CK stimulation by both E2 and by gla. We conclude that glb behaved differently than E2 or gla, but similarly to raloxifene, being a partial agonist/antagonist of E2. Glabridin, on the other hand, demonstrated only estrogenic activity. Therefore, we suggest the use of glb with or without E2 as a new agent for modulation of vascular injury and atherogenesis for the prevention of cardiovascular diseases in post-menopausal women.
_________________________\
This study below is another way, or pathway LR inhibits 5 ar (via P450 3A4 enzyme)
The licorice root derived isoflavan glabridin inhibits the activities of human cytochrome P450S 3A4, 2B6, and 2C9.
Kent UM1, Aviram M, Rosenblat M, Hollenberg PF.
Author information
Abstract
The potent antioxidants licorice root extract and glabridin, an isoflavan purified from licorice root extract, were tested for their ability to modulate the activities of several cytochrome P450 (P450) enzymes. P450 3A4, the major human drug metabolizing P450 enzyme, was inactivated by licorice root extract and by glabridin in a time-and concentration-dependent manner. The inactivation was NADPH-dependent and was not reversible by extensive dialysis. Further analysis showed that the loss in enzymatic activity correlated with a loss in the P450-reduced CO spectrum and with a loss of the intact heme moiety. In contrast, incubations of P450 3A4 with similar concentrations of 2,4-dimethylglabridin and NADPH did not lead to inactivation of P450 3A4. P450 2B6 was also inactivated by glabridin in a time- and concentration-dependent manner. The majority of the glabridin-inactivated P450 2B6 was able to form a reduced CO spectrum suggesting that the heme was not modified with this isoform. High-performance liquid chromatography analysis of the P450 heme confirmed that incubations with glabridin and NADPH did not result in the destruction of the heme moiety. The activity of P450 2C9 was competitively inhibited by glabridin, whereas P450 2D6 and P450 2E1 were virtually unaffected. The data show that glabridin can serve as a substrate for at least three human P450 enzymes and that depending on the isoform, metabolism of glabridin can lead to mechanism-based inactivation or inhibition of the P450. Heme and reduced CO spectral analysis also indicated that glabridin inactivated P450s 2B6 and 3A4 by different mechanisms.
PMID: 12019199 [PubMed - indexed for MEDLINE] Free full text
Shessh, information overload, I'll get to spiro later.......and more on the combo of LR and spiro. gotta run
